Cardiovascular diseases are the primary reason for deaths in the world. However, antiplatelet drugs in the market have limitations in use because of the risk of increased bleeding and other side effects that impair primary homeostasis. Therefore, safe and effective antithrombotic drugs are needed for the treatment of plaque formation in blood vessels. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic therapy. We designed this study based on the molecular interaction pattern of previously published GPVI receptor antagonists within the reported binding site. We selected sixteen hit compounds from a large chemical database that contains>6 million in-stock compounds by following a combined virtual screening. Then, we evaluated their inhibitory effects on platelet aggregation induced by GPVI receptor agonists (collagen, collagen related peptide (CRP), convulxin) and the most potent platelet agonist, thrombin, in vitro by using washed human platelets. IC50 values of compounds 1 and 2 are, respectively, 0.35 μM and 1.01 μM for collagen, 0.80 μM and 1.92 μM for CRP, 195.2 and 7.24 μM for convulxin and 81.38 and 51.74 μM for thrombin. We identified compounds 1 and 2 as the most promising antiplatelet agents out of sixteen compounds. Additionally, compounds 1 and 2 may serve as promising starting points and shed light on the design of new, potent and selective GPVI receptor antagonists.